1. USBC, Inc. changed its name from Know Labs, Inc. 2. The stock will trade under the new ticker symbol 'USBC' from August 15, 2025. 3. A $125M acquisition by Goldeneye 1995 LLC occurred on August 6, 2025. 4. USBC focuses on developing a U.S.-dollar denominated digital deposit token. 5. The company employs a bitcoin treasury strategy for development purposes.

1. DiamiR received NYSDOH approval for its APOE Genotyping test. 2. This test improves Alzheimer's risk assessment and clinical trial enrollment. 3. Aptorum and DiamiR's merger aims to enhance diagnostic capabilities. 4. APOE testing could impact personalized care for neurological diseases. 5. Approval signifies potential growth in brain health diagnostics.

1. PAPZIMEOS is the first FDA-approved therapy for RRP in adults. 2. The approval eliminates the need for further confirmatory clinical trials. 3. RRP affects approximately 27,000 adult patients in the U.S. 4. PAPZIMEOS aims to target the root cause of RRP effectively. 5. Precigen will commence promotion and support programs for PAPZIMEOS.

1. Plymouth received an acquisition proposal at $24.10 per share from Sixth Street. 2. Sixth Street currently owns approximately 9.99% of Plymouth's common stock. 3. The Board will evaluate the offer while ensuring shareholder interests are prioritized. 4. No immediate action is required from shareholders regarding the proposal. 5. KeyBanc is advising Plymouth on this potential acquisition.

1. Rubicon will acquire Janel Group, enhancing capital access. 2. Janel Group had revenues of $181.3 million last year. 3. Rubicon stockholders must approve the merger and related transactions. 4. Janel Corp will own 86.5% of Rubicon post-acquisition. 5. Tender offer for additional shares at $4.75 is pending authority approval.